These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 19463276)

  • 21. Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.
    Mariné M; Pastor FJ; Sahand IH; Pontón J; Quindós G; Guarro J
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5297-9. PubMed ID: 19786599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antifungal activity and clinical efficacy of micafungin sodium (Funguard)].
    Ikeda F
    Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):339-44. PubMed ID: 14501170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anidulafungin: experimental therapy of fungal infections in animal models].
    Pastor FJ; Guarro J
    Rev Iberoam Micol; 2008 Jun; 25(2):119-23. PubMed ID: 18473506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.
    Vehreschild JJ; Cornely OA
    Future Microbiol; 2006 Aug; 1(2):161-70. PubMed ID: 17661660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
    Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive fungal infections: the challenge continues.
    Gullo A
    Drugs; 2009; 69 Suppl 1():65-73. PubMed ID: 19877737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Micafungin versus caspofungin in the treatment of Candida glabrata infection: a case report.
    Yamada SM; Tomita Y; Yamaguchi T; Matsuki T
    J Med Case Rep; 2016 Nov; 10(1):316. PubMed ID: 27821139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
    Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
    Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
    J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].
    Montejo M; Quindós G
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():15-22. PubMed ID: 21420572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Micafungin: a therapeutic review.
    Higashiyama Y; Kohno S
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caspofungin acetate for treatment of invasive fungal infections.
    Pacetti SA; Gelone SP
    Ann Pharmacother; 2003 Jan; 37(1):90-8. PubMed ID: 12503942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antifungal activity and clinical efficacy of micafungin (funguard)].
    Ikeda F
    Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):217-22. PubMed ID: 16282962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Why might micafungin be the drug of choice in pediatric patients?].
    Ramos Amador JT; Prieto Tato L; Guillén Martín S
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
    Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
    J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.